John Paulson has notably reduced his stake in Madrigal Pharmaceuticals, though it remains his largest holding, while the company has issued significant equity grants to new employees. This move, combined with the stock trading below analyst targets and estimated fair value, suggests a reshuffling of influence and a focus on talent acquisition. Investors are advised to monitor insider transactions and share-based compensation as these developments unfold.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Paulson Trims Madrigal Stake As Equity Grants Highlight Valuation Gap
John Paulson has notably reduced his stake in Madrigal Pharmaceuticals, though it remains his largest holding, while the company has issued significant equity grants to new employees. This move, combined with the stock trading below analyst targets and estimated fair value, suggests a reshuffling of influence and a focus on talent acquisition. Investors are advised to monitor insider transactions and share-based compensation as these developments unfold.